Tyrosine kinase inhibitors in treatment of fibrous histiocytoma
Aim: To describe potential beneficial effects of tyrosine kinase inhibitor in the treatment of unresectable/metastatic fibrous histiocytoma. Methods: We report a case of advanced stage fibrous histiocytoma with locally recurrent disease plus lung and bone metastatic deposits. Patient was treated w...
Збережено в:
| Дата: | 2009 |
|---|---|
| Автори: | , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2009
|
| Назва видання: | Experimental Oncology |
| Теми: | |
| Онлайн доступ: | http://dspace.nbuv.gov.ua/handle/123456789/135111 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Tyrosine kinase inhibitors in treatment of fibrous histiocytoma / D. Mauri, C. Panou, A. Valachis, K. Kamposioras, L. Tsali // Experimental Oncology. — 2009. — Т. 31, № 1. — С. 60-61. — Бібліогр.: 18 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| Резюме: | Aim: To describe potential beneficial effects of tyrosine kinase inhibitor in the treatment of unresectable/metastatic fibrous histiocytoma.
Methods: We report a case of advanced stage fibrous histiocytoma with locally recurrent disease plus lung and bone
metastatic deposits. Patient was treated with the tyrosine kinase inhibitor sunitinib. Results: Treatment with Sunitinib resulted in
disease stabilization in the regional lesion and in good partial response for metastatic foci (reduction in number and size). After
13 months of treatment the patient is doing well with no tumor progression. Conclusions: This case appears to be one of the first
documentations of beneficial effect and potential long-term benefit of TKIs in the treatment of fibrous histiocytoma. |
|---|